The role of IL‐6 in immunotherapy of non‐small cell lung cancer (NSCLC) with immune‐related adverse events (irAEs)
Wanhai Ke, Li Zhang, Yan Dai
Abstract
IL-6 is a cytokine that plays an important role in response to injury or infection and is a promising biomarker for predicting poor prognosis and therapeutic targets in non-small cell lung cancer (NSCLC). This article reviews the biochemical mechanism, function and genotype of IL-6, and summarizes the diagnostic and prognostic value of IL-6 level. Anti-IL-6 therapy does not affect the effect of immunocheckpoint inhibitors (ICIs), but enhances its anticancer function, which may be the treatment option for immune-related adverse events (irAEs) in the future. Therefore, IL-6 may be a therapeutic target for the treatment of NSCLC.
Topics & Concepts
MedicineLung cancerAdverse effectImmunotherapyImmune systemOncologyBiomarkerMechanism (biology)Internal medicineImmunologyBioinformaticsPhilosophyEpistemologyBiochemistryChemistryBiologyCAR-T cell therapy researchCancer Research and TreatmentsCancer Immunotherapy and Biomarkers